Verve un­veils ear­ly da­ta from sec­ond at­tempt at heart dis­ease gene edit­ing

Verve Ther­a­peu­tics is try­ing to swerve the gene edit­ing in­dus­try down­turn with new re­sults on a po­ten­tial one-time treat­ment to low­er cho­les­terol.

The ex­per­i­men­tal gene …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER